activities at the National Institutes of Health, as well as 
to discuss and solicit input related to potential areas of 
collaboration between the National Institutes of Health 
and other Federal health agencies, including the Centers 
for Disease Control and Prevention, the Administration on 
Aging, the Agency for Healthcare Research and Quality, 
and the Health Resources and Services Administration, 
related to research, prevention, and treatment of Alz-
heimer’s disease. 
(b) FOCUS AREAS.—The summit convened under 
subsection (a) shall focus on— 
(1) a broad range of Alzheimer’s disease re-
search activities relating to biomedical research, pre-
vention research, and caregiving issues; 
(2) clinical research for the development and 
evaluation of new treatments for the disease; 
(3) translational research on evidence-based and 
cost-effective best practices in the treatment and 
prevention of the disease; 
(4) information and education programs for 
health care professionals and the public relating to 
the disease; 
(5) priorities among the programs and activities 
of the various Federal agencies regarding such dis-
eases; and 
VerDate Aug 31 2005 
23:21 Mar 20, 2007
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H1560.IH
H1560
ycherry on PROD1PC64 with BILLS
(6) challenges and opportunities for scientists, 
clinicians, patients, and voluntary organizations re-
lating to the disease. 
(c) REPORT.—Not later than 180 days after the date 
on which the National Summit on Alzheimer’s Disease is 
convened under subsection (a), the Director of National 
Institutes of Health shall prepare and submit to the ap-
propriate committees of Congress a report that includes 
a summary of the proceedings of the summit and a de-
scription of Alzheimer’s research, education, and other ac-
tivities that are conducted or supported through the na-
tional research institutes. 
(d) PUBLIC INFORMATION.—The Secretary shall 
make readily available to the public information about the 
research, education, and other activities relating to Alz-
heimer’s disease and other related dementias, conducted 
or supported by the National Institutes of Health. 
VerDate Aug 31 2005 
23:21 Mar 20, 2007
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H1560.IH
H1560
ycherry on PROD1PC64 with BILLS
TITLE II—PUBLIC HEALTH PRO-
MOTION 
AND 
PREVENTION 
OF ALZHEIMER’S DISEASE 
SEC. 201. ENHANCING PUBLIC HEALTH ACTIVITIES RE-
LATED TO COGNITIVE HEALTH, ALZHEIMER’S 
DISEASE, AND OTHER DEMENTIA’S. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 399R. ALZHEIMER’S DISEASE PUBLIC EDUCATION 
CAMPAIGN. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, shall directly or through grants, cooperative 
agreements, or contracts to eligible entities, conduct, sup-
port, and promote the coordination of research, investiga-
tions, demonstrations, training, and studies relating to the 
control, prevention, and surveillance of the risk factors as-
sociated with cognitive health, Alzheimer’s disease, and 
other dementias, and seek early recognition and interven-
tion in the course of Alzheimer’s disease and other demen-
tias. 
‘‘(b) CERTAIN ACTIVITIES.—Activities under sub-
section (a) shall include— 
VerDate Aug 31 2005 
23:21 Mar 20, 2007
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H1560.IH
H1560
ycherry on PROD1PC64 with BILLS
‘‘(1) providing support for the dissemination 
and implementation of the Roadmap to Maintaining 
Cognitive Health to effectively mobilize the public 
health community into action; 
‘‘(2) the development of coordinated public edu-
cation programs, services, and demonstrations which 
are designed to increase general awareness of cog-
nitive function and promote a brain healthy lifestyle; 
‘‘(3) the development of targeted communica-
tion strategies and tools to educate health profes-
sionals and service providers about the early recogni-
tion, diagnosis, care, and management of Alz-
heimer’s disease and dementia, and to provide con-
sumers with information about interventions, prod-
ucts, and services that promote cognitive health and 
assist consumers in maintaining current under-
standing about cognitive health based on the best 
science available; and 
‘‘(4) provide support for the collection, publica-
tion, and analysis of data on the prevalence and inci-
dence of cognitive health, Alzheimer’s disease, and 
other dementias, and the evaluation of existing pop-
ulation-based surveillance systems (such as the Be-
havioral Risk Factors Surveillance Survey (BRFFS) 
and the National Health Interview Survey (NHIS)) 
VerDate Aug 31 2005 
23:21 Mar 20, 2007
Jkt 059200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H1560.IH
H1560
ycherry on PROD1PC64 with BILLS
to identify limitations that exist in the area of cog-
nitive health, and if necessary, the development of a 
surveillance system for cognitive decline, including 
Alzheimer’s disease and dementia. 
‘‘(c) GRANTS.—The Secretary may award grants 
under this section— 
‘‘(1) to State and local health agencies for the 
purpose of— 
‘‘(A) coordinating activities related to cog-
nitive health, Alzheimer’s disease, and other de-
mentias with existing State-based health pro-
grams and community-based organizations; 
‘‘(B) providing Alzheimer’s disease edu-
cation and training opportunities and programs 
for health professionals; and 
‘‘(C) developing, testing, evaluating, and 
replicating effective Alzheimer’s disease inter-
vention programs to maintain or improve cog-
nitive health; and 
‘‘(2) to nonprofit private health organizations 
with expertise in providing care and services to indi-
viduals with Alzheimer’s disease for the purpose 
of— 
‘‘(A) disseminating information to the pub-
lic; 
VerDate Aug 31 2005 
23:21 Mar 20, 2007
Jkt 059200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H1560.IH
H1560
ycherry on PROD1PC64 with BILLS